← Leaderboards
Joshua Kennedy
Arkansas Children'S Hospital Res Inst
$4,276,909
Attributed
$7,313,974
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2016–25$2.5M$1.9M$1.3M$625K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,313,974 · 5
By mechanism
R44$3,043,597 · 1
K12$1,512,000 · 1
R01$1,362,012 · 1
K08$948,780 · 1
R21$447,585 · 1
Top collaborators
- David H Broide3 shared
- Yakov Kogan3 shared
- Jason Eli Farrar2 shared
- Mario Schootman2 shared
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionRhinovirusVirus DiseasesChildViralLungCytokineReceptorAsthmaImmuneAsthmaticEpithelial CellsAirway HyperresponsivenessPathway InteractionsAgonistCellsSliceResponsePediatric HospitalsArkansasImmune ResponseSymptomsResearch PersonnelUniversities
Grant awards (14)
Targeting lipid rafts for treatment of asthma$1,046,403
R44 · FY2025 · AI
CTSA K12 Program at the University of Arkansas for Medical Sciences$756,000
K12 · FY2025 · TR
An Integrated Host-Microbe Gene Classifier to Predict SARS-CoV-2 and Severe Disease in Children with Respiratory Viral Coinfections$667,609
R01 · FY2025 · HL · contact PI
Targeting lipid rafts for treatment of asthma$997,203
R44 · FY2024 · AI
CTSA K12 Program at the University of Arkansas for Medical Sciences$756,000
K12 · FY2024 · TR
An Integrated Host-Microbe Gene Classifier to Predict SARS-CoV-2 and Severe Disease in Children with Respiratory Viral Coinfections$694,403
R01 · FY2024 · HL · contact PI
Targeting lipid rafts for treatment of asthma$999,991
R44 · FY2023 · AI
ORMDL3 Stimulated ICAM1 and RVA-induced Childhood Asthma Exacerbations$231,726
R21 · FY2022 · AI · contact PI
ORMDL3 Stimulated ICAM1 and RVA-induced Childhood Asthma Exacerbations$215,859
R21 · FY2021 · AI · contact PI
Examining Mechanisms of Synergy between Asthma Exacerbations and RV Infection$193,320
K08 · FY2020 · AI · contact PI
Examining Mechanisms of Synergy between Asthma Exacerbations and RV Infection$193,320
K08 · FY2019 · AI · contact PI
Examining Mechanisms of Synergy between Asthma Exacerbations and RV Infection$193,320
K08 · FY2018 · AI · contact PI
Examining Mechanisms of Synergy between Asthma Exacerbations and RV Infection$193,320
K08 · FY2017 · AI · contact PI
Examining Mechanisms of Synergy between Asthma Exacerbations and RV Infection$175,500
K08 · FY2016 · AI · contact PI